Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer

Sponsor
Fudan University
Study ID
NCT05407155
Status
Active Not Recruiting

Conditions

  • Non-small Cell Lung Cancer Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab plus nab-paclitaxel and platinum — COMBINATION_PRODUCT
    Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.

Study Details

Immune checkpoint inhibitor (ICI)-based regimen has been widely used in first-line treatment of driver-gene-negative non-squamous non-small cell lung cancer. This study investigate the efficacy and safety of the combination of bevacizumab plus nab-paclitaxel and platinum as second-line treatment for driver-gene-negative non-squamous non-small cell lung cancer patients progressed after ICI-based treatments.

Key Dates

First listed
Jun 7, 2022
Start date
Jun 9, 2022
Status verified
Apr 2026
Primary completion
Apr 15, 2026
Completion
Aug 30, 2026

Study Design

Enrollment
56 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental arm
    Patients received bevacizumab plus nab-paclitaxel and platinum as second-line therapy.

Primary Outcome Measure

Objective response rate [ Time Frame: From enrollment to end of study, up to 2 years ]

Related Studies